Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)

Early clinical evidence of VRN110755: A novel brain-penetrant EGFR TKI active across common, uncommon, and resistance EGFR mutations

Enozertinib (ORIC-114), a brain penetrant, highly selective EGFR inhibitor, in treatment-naive metastatic NSCLC with EGFR atypical mutations

Telisotuzumab adizutecan (temab-A) for EGFR-mutated (mut) nonsquamous non-small cell lung cancer (NSQ NSCLC): Post hoc analysis from a phase 1 first-in-human (FIH) study in patients (pts) with brain metastases (BMs)

Osimertinib (osi) rechallenge after interstitial lung disease (ILD) during osi treatment (tx) in EGFR-mutated advanced non-small cell lung cancer (NSCLC): A retrospective chart review study

Dose modifications to manage adverse events (AEs) in 1L EGFR-mutated advanced NSCLC: Post hoc, exploratory analyses from the phase 3 MARIPOSA trial